



Charting of the logistic challenges in conjunction with the prospective sampling

The following table charts the challenges and solutions with regards to some practical considerations

Challenge	Solution	Lobsterpot
ILC is a rare breast cancer type (15% of all BC)	Network to be built to join forces (to get sufficient ILC patients, samples and data)	Lobsterpot has built this international network of clinicians and scientists
ILC pathological diagnosis currently suboptimal and not homogeneous across the world	Need of a dedicated study evaluating the commonly used E-cadherin IHC markers	Lobsterpot is conducting a ring study (WG2 and WG3)
Samples collection is not sufficiently standardized	Clear guidelines on which samples to be collected and how	Lobsterpot has drafted several SOPs (WG3)
<i>In vivo</i> models are missing for ILC	Need of dedicated sample collection and experts in the fields	Lobsterpot is collecting these samples and <i>in vivo</i> models are derived (WG3 and WG5)
Diverse mechanisms of sensitivity and resistance to treatments in ILC	Need of dedicated translational research (TR) on ILC	Lobsterpot has built this strong TR focus and is building a centralized biobank
No dedicated trials for ILC patients	Need of dedicated experts to design these trials based on basic research and TR with clear samples collection plan.	Lobsterpot has built this network with dedicated experts who are benefiting from the work done in the diverse WGs: availability of ILC patients to enter the trials, ILC diagnosis to be eligible, sample collection guidelines (including <i>in vivo</i> models development)